NDC product
COSELA
NDC 73462-101 · G1 Therapeutics, Inc.
Key facts
| Product NDC | 73462-101 |
|---|---|
| Proprietary name | COSELA |
| Nonproprietary name | trilaciclib |
| Substances | TRILACICLIB DIHYDROCHLORIDE |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAVENOUS |
| Labeler | G1 Therapeutics, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA214200 |
| Pharmacologic classes | Cyclin-dependent Kinase 4 Inhibitors [MoA], Cyclin-dependent Kinase 6 Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 2 K Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA] |
| Marketing start | Feb 12, 2021 |
| Marketing end | Dec 31, 2028 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory